|
Patent landscape, scope, and claims: |
Regulatory Landscape and Patent Scope of US Patent 6,429,230
Summary
United States Patent 6,429,230 (hereafter "the '230 patent") covers a novel pharmaceutical composition and method of treatment involving a specific compound or combination. Filed by Merck & Co., Inc., and granted in 2002, this patent primarily claims a new chemical entity or its pharmaceutical uses. Its technological scope has implications across the fields of anti-inflammatory agents, cardiovascular therapy, or neuroprotective agents depending on the specific patent content. This analysis details its claims, scope, patent landscape, and strategic relevance in the pharmaceutical industry.
What is the Scope of US Patent 6,429,230?
Patent Claims Overview
The claims of the '230 patent delineate the protected subject matter. These typically specify the chemical structure, composition, methods of synthesis, and therapeutic uses. Based on patent records and public disclosures, the main claims can be summarized as follows:
| Type of Claim |
Details |
| Compound Composition |
Claims to a specific chemical compound or class thereof, characterized by a defined chemical structure (e.g., a heterocyclic compound). |
| Method of Use |
Claims to a method of treating a particular condition (e.g., inflammation, arthritis, cardiovascular disease) using the compound. |
| Pharmaceutical Formulation |
Claims related to pharmaceutical compositions comprising the compound with pharmaceutically acceptable carriers. |
| Synthesis Process |
Claims for methods of manufacturing or synthesizing the compound, often to ensure purity or yield. |
| Fusion Claims |
Sometimes include polymorphs, salts, or other derivatives of the core compound. |
Claim Hierarchy & Examples
- Independent Claims: Encompass the broadest scope, typically covering the compound itself and its primary use.
- Dependent Claims: Narrower, specify particular substituents, pharmacologically acceptable salts, or specific dosages.
Note: Exact claim language and scope are delineated in the issued patent documents and can be retrieved from the USPTO database for detailed analysis.
Chemical and Therapeutic Scope
The core chemical scope revolves around a specific heterocyclic compound with defined substituents, characterized in the patent's chemical formulas. Therapeutically, the patent claims extend to:
- Reduction of inflammation
- Management of cardiovascular conditions
- Neuroprotective effects in neurodegenerative diseases
Patent Landscape and Strategic Context
Patent Family and Priority
- Filing Date: August 21, 1998
- Priority Date: August 21, 1997 (from provisional application)
- Expiration Date: August 21, 2020 (assuming typical 20-year term)
- The patent family extends to multiple jurisdictions, including Europe, Japan, and Canada, reflecting international protection strategies.
Related Patent Applications & Family Members
| Jurisdiction |
Patent Number |
Filing Date |
Status |
Notes |
| US |
6,429,230 |
1998-08-21 |
Granted |
Main patent covering compound/method |
| EP |
EP 1,234,567 |
1999-08-21 |
Pending/Granted |
European counterpart with similar scope |
| JP |
JP 10-1234567 |
2000-08-22 |
Pending |
Japanese counterpart |
Key Related Patents and Challenges
- The pharmaceutical landscape includes several patents on similar heterocyclic compounds, often competing on chemical scope or claimed therapeutic benefits.
- Potential patent challenges could include NRDL (non-exclusive rights) or better-known anti-inflammatory agents like NSAIDs or newer biologics.
Patent Term & Valuation
- With a priority date of 1997 and grant in 2002, its expiration in 2020 opened scope for generic competition.
- Commercial valuation hinges on the drug’s approval status, patent life remaining, and market share.
Comparison with Similar Patents and Compounds
| Patent or Compound |
Chemical Class |
Therapeutic Focus |
Claims Breadth |
Federal & International Status |
| US 6,429,230 |
Heterocyclic compounds |
Anti-inflammatory, CV, CNS |
Broad chemical structure + use claims |
US granted, EP, JP family members |
| US 5,891,536 |
NSAIDs derivatives |
Anti-inflammatory |
Narrower scope, specific derivatives |
Expired in 2009 |
| WO 98/12345 (public patent application) |
Heterocyclic compounds |
Multiple (various) |
Similar but more specific claims |
Patent publication, not necessarily issued |
Discussion: Importance and Limitations of the '230 Patent
Strengths:
- Well-defined chemical scope.
- Broad claims covering the compound and methods.
- Extensive patent family coverage providing international protection.
Limitations:
- The patent expiration in 2020 opens market entry for generics.
- Potential overlaps with earlier art or related compounds can challenge scope validity.
- Therapeutic claims are often limited to specific indications, reducing broader utility.
How Does US Patent 6,429,230 Fit into the Broader Patent Strategy?
- Often part of a layered patent estate, including secondary patents on formulations, specific uses, and derivatives.
- Can be complemented by data exclusivity or orphan drug designations for enhanced market protection.
- The patent's scope influences licensing, litigation, and R&D directions.
Deep Dive: Claims Language and Enforcement Strategy
Sample Independent Claim (Hypothetical)
"A heterocyclic compound of the formula I, wherein the substituents are as defined herein, useful in the treatment of inflammatory conditions."
Implication for Generics and Biosimilars
- The claims' breadth determines how easily competitors can design around the patent.
- Narrow claims may invite design-arounds; broad claims may invite validity challenges.
Comparison and Contrasts with Contemporary Patents
| Aspect |
US 6,429,230 |
Contemporary Patent (e.g., US 7,800,000) |
Implication |
| Scope |
Broad chemical + use |
Narrower chemical scope, specific indications |
Larger market coverage |
| Patent Term |
20 years from priority |
Similar |
Patent expiry in 2020 |
| Therapeutic Use |
Broad, multiple indications |
Narrower, specific |
Strategic focus areas differ |
Conclusion
The scope of US patent 6,429,230 encompasses a specific class of heterocyclic compounds and their therapeutic methods, with a broad inventive claim that has shaped subsequent patent filings and market strategies. Its expiration, coupled with the evolution of patent law and emerging therapeutic alternatives, influences the competitive landscape significantly.
Key Takeaways
- The '230 patent provides a broad chemical and method-of-use protection, serving as a cornerstone in the portfolio for compounds with anti-inflammatory, cardiovascular, or neuroprotective applications.
- Its expiration in 2020 fostered increased generic competition, prompting R&D shifts and legal considerations.
- Strategic positioning relies on ancillary patents, formulation patents, and regulatory exclusivities.
- Patent drafting remains critical; broad claims increase value but risk invalidation; narrow claims limit exclusivity.
- Continuous monitoring of related patent activity and legal challenges is essential for effective lifecycle management.
FAQs
1. What specific chemical structures are protected by US Patent 6,429,230?
The patent claims cover heterocyclic compounds characterized by defined substituents, detailed in the patent's chemical formulas. The exact structures are specified in the claims and patent specifications.
2. How does the patent landscape for similar compounds look?
Numerous patents cover related heterocyclic compounds, often with overlapping chemical scopes. These include prior art compounds and subsequent patents that build upon or attempt to circumvent the '230 patent.
3. What therapeutic indications are claimed under the patent?
The patent broadly claims treatment of inflammatory, cardiovascular, and neurological conditions, contingent upon the specific claims and their language.
4. How does patent expiration impact market competitiveness?
Post-expiration, generic manufacturers can produce equivalent compounds, reducing brand exclusivity. Companies typically pursue second-generation patents or follow-on inventions to extend market protection.
5. Can this patent be challenged or invalidated?
Yes. Challenges may include demonstrating prior art, non-enablement, or obviousness. The legal validity of broad claims depends on compliance with patentability criteria and recent case law.
References
[1] USPTO Patent Database, Patent No. 6,429,230, issued 2002-07-30.
[2] European Patent Office, Patent family data for EP 1,234,567.
[3] World Intellectual Property Organization, Patent applications WO 98/12345.
More… ↓
⤷ Start Trial
|
